<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<!-- saved from url=(0052)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/ -->
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="brjclinpharm"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC3477350/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="./PMC3477350_files/jig.min.css"><script type="text/javascript" src="./PMC3477350_files/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="British Journal of Clinical Pharmacology"><meta name="citation_title" content="Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin"><meta name="citation_authors" content="Sebastian Härtter, Michael Koenen-Bergmann, Ashish Sharma, Gerhard Nehmiz, Ute Lemke, Wolfgang Timmer, Paul A Reilly"><meta name="citation_date" content="September 2012"><meta name="citation_issue" content="3"><meta name="citation_volume" content="74"><meta name="citation_firstpage" content="490"><meta name="citation_doi" content="10.1111/j.1365-2125.2012.04218.x"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC3477350/?report=abstract"><meta name="citation_pmid" content="22348256"><meta name="DC.Title" content="Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="Wiley-Blackwell"><meta name="DC.Contributor" content="Sebastian Härtter"><meta name="DC.Contributor" content="Michael Koenen-Bergmann"><meta name="DC.Contributor" content="Ashish Sharma"><meta name="DC.Contributor" content="Gerhard Nehmiz"><meta name="DC.Contributor" content="Ute Lemke"><meta name="DC.Contributor" content="Wolfgang Timmer"><meta name="DC.Contributor" content="Paul A Reilly"><meta name="DC.Date" content="2012 Sep"><meta name="DC.Identifier" content="10.1111/j.1365-2125.2012.04218.x"><meta name="DC.Language" content="en"><meta property="og:title" content="Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin"><meta property="og:type" content="article"><meta property="og:description" content="This study examined the effects of the CYP3A/P-glycoprotein inducer, rifampicin, on the pharmacokinetics of dabigatran following oral administration of the prodrug, dabigatran etexilate.This was an open-label, fixed-sequence, four-period study in healthy ..."><meta property="og:url" content="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><link rel="stylesheet" href="./PMC3477350_files/pmc.min.css" type="text/css"><link rel="stylesheet" href="./PMC3477350_files/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="./PMC3477350_files/common.min.js">//</script><script type="text/javascript" src="./PMC3477350_files/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:&#39;/pmc/utils/ctxp/&#39;"><script type="text/javascript" src="./PMC3477350_files/jquery.citationexporter.js">//</script><link rel="stylesheet" href="./PMC3477350_files/citationexporter.css" type="text/css"><script type="text/javascript" src="./PMC3477350_files/MathJax.js"></script><script type="text/javascript" src="./PMC3477350_files/large-obj-scrollbars.min.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><link rel="alternate" type="application/epub+zip" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/epub/"><link rel="alternate" type="application/pdf" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/pdf/bcp0074-0490.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="http://www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="F4FC36FE76C29E21000000000095A6B5"><link type="text/css" rel="stylesheet" href="./PMC3477350_files/3855312.css"><link type="text/css" rel="stylesheet" href="./PMC3477350_files/3929378.css" media="print"><style type="text/css" media="print">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }.print-log li { list-style-image: url('http://www.ncbi.nlm.nih.gov/stat?jsevent=print&ncbi_app=pmc&ncbi_db=pmc&ncbi_pcid=%2Farticles%2FPMC3477350%2F&ncbi_pdid=article&ncbi_phid=F4FC36FE76C29E21000000000095A6B5'); }</style><style type="text/css">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-jig-5"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	&lt;p class="nojs"&gt;
	&lt;strong&gt;Warning:&lt;/strong&gt;
	The NCBI web site requires JavaScript to function. 
	&lt;a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank"&gt;more...&lt;/a&gt;
	&lt;/p&gt;
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="http://www.ncbi.nlm.nih.gov/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="./PMC3477350_files/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="http://www.ncbi.nlm.nih.gov/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="http://www.ncbi.nlm.nih.gov/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3477350%2F" id="sign_in">Sign in to NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/signout/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3477350%2F" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="http://www.ncbi.nlm.nih.gov/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="http://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="http://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="http://www.ncbi.nlm.nih.gov/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="clone">Clone</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="nucest">EST</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="nucgss">GSS</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="pubmedhealth">PubMed Health</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbook">ToolKitBook</option><option value="toolkitbookgh">ToolKitBookgh</option><option value="unigene">UniGene</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="ui-ncbiclearbutton-wrap box-shadow"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config="dictionary:&#39;pmc-search-autocomplete&#39;,disableUrl:&#39;NcbiSearchBarAutoComplCtrl&#39;" autocomplete="off" data-sbconfig="ds:&#39;no&#39;,pjs:&#39;no&#39;,afs:&#39;yes&#39;" aria-haspopup="true" aria-autocomplete="list" role="textbox"><a class="reset" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" style="visibility: hidden;"><img src="./PMC3477350_files/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/limits/">Limits</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="http://www.ncbi.nlm.nih.gov/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="http://www.ncbi.nlm.nih.gov/pmc/journals/" class="navlink">Journal List</a></li><li class="archive-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/journals/279/">Br J Clin Pharmacol</a></li><li class="issue-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/issues/215557/">v.74(3); 2012 Sep</a></li><li class="accid">PMC3477350</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="./PMC3477350_files/logo-brjclinpharm.gif" alt="Logo of brjclinpharm" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher&#39;s site" title="Link to Publisher&#39;s site" shape="default" coords="0,0,499,74" href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251" target="pmc_ext" ref="reftype=publisher&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [&#39;h2&#39;], headingExclude: &#39;:hidden&#39;" id="ui-jig-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="small"><div class="inline_block eight_col va_top"><div><div><span class="cit">Br J Clin Pharmacol. 2012 Sep; 74(3): 490–500. </span></div><div><span class="fm-vol-iss-date">Published online 2012 Feb 20. </span>  <span class="doi">doi:&nbsp; <a href="http://dx.doi.org/10.1111%2Fj.1365-2125.2012.04218.x" target="pmc_ext" ref="reftype=other&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">10.1111/j.1365-2125.2012.04218.x</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC3477350</span></div></div></div></div></div><h1 class="content-title">Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=H%26%23x000e4%3Brtter%20S%5Bauth%5D">Sebastian Härtter</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Koenen-Bergmann%20M%5Bauth%5D">Michael Koenen-Bergmann</a>,<sup>2</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Sharma%20A%5Bauth%5D">Ashish Sharma</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Nehmiz%20G%5Bauth%5D">Gerhard Nehmiz</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Lemke%20U%5Bauth%5D">Ute Lemke</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Timmer%20W%5Bauth%5D">Wolfgang Timmer</a>,<sup>3</sup> and  <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Reilly%20PA%5Bauth%5D">Paul A Reilly</a><sup>4</sup></div></div><div class="fm-panel small half_rhythm"><div class="fm-authors-info fm-panel hide half_rhythm" id="id1070052_ai" style="display:none"><div class="fm-affl" lang="en"><sup>1</sup>Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorfer Straße 65, 88397 Biberach/Riss</div><div class="fm-affl" lang="en"><sup>2</sup>Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Binger Straße 173, 55216 Ingelheim</div><div class="fm-affl" lang="en"><sup>3</sup>CRS Mannheim GmbH, Grenadierstraße 1, 68167 Mannheim, Germany</div><div class="fm-affl" lang="en"><sup>4</sup>Boehringer Ingelheim Pharma, 900 Ridgebury Road, Ridgefield, CT 06877-1058, USA</div><div id="cor1">Dr Sebastian Härtter, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Translational Medicine, Birkendorfer Straße 65, 88397 Biberach/Riss, Germany. Tel.: +49 7351 54 5950. Fax: +49 7351 54 90170. E-mail: <a href="mailto:dev@null" data-email="moc.miehlegni-regnirheob@rettreah.naitsabes" class="oemail">moc.miehlegni-regnirheob@rettreah.naitsabes</a></div></div><div class="togglers"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" class="pmctoggle" rid="id1070052_ai">Author information <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" class="pmctoggle" rid="id1070052_an">Article notes <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" class="pmctoggle" rid="id1070052_cpl">Copyright and License information <span>►</span></a></div><div class="fm-article-notes fm-panel hide half_rhythm" id="id1070052_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2011 Sep 13; Accepted 2012 Feb 14.</div></div><div class="fm-cpl-info fm-panel hide half_rhythm" id="id1070052_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright</a>  © 2012 The British Pharmacological Society</div></div></div><div class="links-box fm-panel whole_rhythm"><div class="small"><div>This article has been <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="__abstractid753267" lang="en" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-7"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true" id="ui-jig-8">Go to:</a></span></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__abstractid753267title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3>AIMS</h3><p id="__p1" class="p p-first-last">This study examined the effects of the CYP3A/P-glycoprotein inducer, rifampicin, on the pharmacokinetics of dabigatran following oral administration of the prodrug, dabigatran etexilate.</p></div><div id="__sec2" class="sec"><h3>METHODS</h3><p id="__p2" class="p p-first-last">This was an open-label, fixed-sequence, four-period study in healthy volunteers. Subjects received a single dose of dabigatran etexilate 150 mg on day 1, rifampicin 600 mg once daily on days 2–8, and single doses of dabigatran etexilate on days 9, 16 and 23.</p></div><div id="__sec3" class="sec"><h3>RESULTS</h3><p id="__p3" class="p p-first-last">Twenty-four subjects were treated, of whom 22 received all treatments. Relative to the reference (single dose of dabigatran etexilate alone; treatment A), administration of dabigatran etexilate following 7 days of rifampicin (treatment B) decreased the geometric mean (gMean) area under the concentration–time curve (AUC<sub>0–∞</sub>) and maximal plasma concentration (<em>C</em><sub>max</sub>) of total dabigatran by 67 and 65.5%, respectively. The time to peak and the terminal half-life were not affected. The gMean ratio for the primary comparison (treatment B <em>vs</em>. treatment A) was 33.0% (90% confidence interval 26.5, 41.2%) for AUC<sub>0–∞</sub> and 34.5% (90% confidence interval 26.9, 44.1%) for <em>C</em><sub>max</sub>, indicating a significant effect on total dabigatran exposure (total pharmacologically active dabigatran represents the sum of nonconjugated dabigatran and dabigatran glucuronide). After a 7 day (treatment C) or 14 day washout (treatment D), the AUC<sub>0–∞</sub> and <em>C</em><sub>max</sub> of dabigatran were reduced by 18 and 20%, and by 15 and 20%, respectively, compared with treatment A, which was considered not clinically relevant. The overall safety profile of all treatments was good.</p></div><div id="__sec4" class="sec sec-last"><h3>CONCLUSIONS</h3><p id="__p4" class="p p-first-last">Administration of rifampicin for 7 days resulted in a significant reduction in the bioavailability of dabigatran, which returned almost to baseline after 7 days washout.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">dabigatran etexilate, drug interaction, P-glycoprotein, rifampicin</span></div></div><div id="__bodyid1051234" class="tsec sec headless whole_rhythm"><div class="boxed-text-box whole_rhythm hide-overflow"><div class="sec"><h3>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT</h3><div id="__p5"><ul class="unordered" style="list-style-type:disc"><!--
list-behavior=unordered
prefix-word=
mark-type=disc
--><li><div>Dabigatran etexilate is an oral prodrug that is rapidly converted to dabigatran, a direct and reversible thrombin inhibitor.</div></li><li><div>Dabigatran etexilate and dabigatran are not metabolized by the cytochrome P450 system, and dabigatran does not affect the metabolism of other drugs that utilize this system, leading to a low potential for drug–drug interactions.</div></li><li><div>Dabigatran etexilate, but not dabigatran, is a P-glycoprotein (P-gp) substrate, and the bioavailability of dabigatran may be altered by P-gp inhibitors or inducers.</div></li></ul></div></div></div><div class="boxed-text-box whole_rhythm hide-overflow"><div class="sec"><h3>WHAT THIS STUDY ADDS</h3><div id="__p9"><ul class="unordered" style="list-style-type:disc"><!--
list-behavior=unordered
prefix-word=
mark-type=disc
--><li><div>Administration of rifampicin (a strong P-gp inducer) for 7 days before a single dose of dabigatran etexilate resulted in a significant reduction in the bioavailability of dabigatran compared with administration of dabigatran etexilate alone.</div></li><li><div>Within 7 days following the cessation of rifampicin administration, the bioavailability of dabigatran returned almost to baseline values.</div></li><li><div>Rifampicin is not recommended for use with dabigatran etexilate because of the potential for reduced systemic exposure to dabigatran.</div></li></ul></div></div></div></div><div id="__sec7" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-9"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-10">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec7title">Introduction</h2><p id="__p13" class="p p-first">Dabigatran etexilate is an oral prodrug that is rapidly converted via two intermediates, BIBR 1087 SE and BIBR 951 BS, to the active moiety, dabigatran, a direct and reversible thrombin inhibitor. Dabigatran is partly conjugated with activated glucuronic acid to form a pharmacologically equipotent glucuronide. Free dabigatran and total dabigatran (sum of free and glucuronidated dabigatran) reach peak plasma concentrations after approximately 1.5 h, have a half-life of 12–17 h and are predominantly excreted (&gt;80%) via the kidneys [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b1" rid="b1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079372" role="button" aria-expanded="false" aria-haspopup="true">1</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b6" rid="b6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079362" role="button" aria-expanded="false" aria-haspopup="true">6</a>].</p><p id="__p14">Dabigatran etexilate is licensed for the prevention of venous thromboembolic events following total hip or knee replacement and has more recently been approved and marketed for stroke prevention in patients with atrial fibrillation [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b7" rid="b7" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">7</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b9" rid="b9" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">9</a>]. Dabigatran etexilate is administered orally, is not associated with clinically relevant food interactions and has dose-proportional and linear pharmacokinetics (PK) and pharmacodynamics (PD) [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b2" rid="b2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079379" role="button" aria-expanded="false" aria-haspopup="true">2</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b3" rid="b3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079364" role="button" aria-expanded="false" aria-haspopup="true">3</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b10" rid="b10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079377" role="button" aria-expanded="false" aria-haspopup="true">10</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b13" rid="b13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079378" role="button" aria-expanded="false" aria-haspopup="true">13</a>].</p><p id="__p15">Dabigatran etexilate and dabigatran are not metabolized by the cytochrome P450 (CYP) system, and dabigatran does not affect the metabolism of other drugs that utilize this system [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b2" rid="b2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079361" role="button" aria-expanded="false" aria-haspopup="true">2</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b14" rid="b14" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">14</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b16" rid="b16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079375" role="button" aria-expanded="false" aria-haspopup="true">16</a>]. However, preclinical and clinical studies have shown that dabigatran etexilate (but not dabigatran) is a P-glycoprotein (P-gp) substrate, and therefore the bioavailability of dabigatran following oral administration of dabigatran etexilate may be altered by P-gp inhibitors [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b17" rid="b17" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">17</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b18" rid="b18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079369" role="button" aria-expanded="false" aria-haspopup="true">18</a>]. For example, its bioavailability is increased in patients taking strong P-gp inhibitors, such as quinidine, verapamil and amiodarone.</p><p id="__p16">The antibacterial agent rifampicin (used primarily in the treatment of tuberculosis) is a strong inducer of intestinal and hepatic P-gp. It also induces a number of drug-metabolizing enzymes, having the greatest effects on the expression of CYP3A in the liver and small intestine [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b19" rid="b19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079360" role="button" aria-expanded="false" aria-haspopup="true">19</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b20" rid="b20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079373" role="button" aria-expanded="false" aria-haspopup="true">20</a>].</p><p id="__p17">The primary objective of the trial was to determine whether, and to what extent, the P-gp inducer, rifampicin, affects the plasma exposure of dabigatran by investigating the effect of multiple doses of rifampicin 600 mg once daily on the PK parameters of dabigatran following a single dose of 150 mg dabigatran etexilate. The study also evaluated the time course of a return to normal availability of dabigatran, which could be interpreted as normal activity levels of P-gp after induction by rifampicin. The doses selected for investigation reflect standard clinical doses of rifampicin and dabigatran etexilate, and were expected to allow an adequate determination of the PK parameters of dabigatran after P-gp induction. The induction by rifampicin was to be confirmed further by measurement of a surrogate end-point, the urinary 6β-hydroxycortisol/cortisol ratio. This ratio is thought to reflect the CYP3A activity and has proved to be a good marker for CYP3A induction [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b21" rid="b21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079370" role="button" aria-expanded="false" aria-haspopup="true">21</a>].</p><p id="__p18" class="p p-last">The secondary objectives were to determine the safety and tolerability of dabigatran and rifampicin coadministration, and to determine the duration of the effect of P-gp induction after cessation of rifampicin treatment. If an interaction between rifampicin and dabigatran was observed, it was expected that this would lead to decreased dabigatran exposure.</p></div><div id="__sec8" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-11"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-12">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec8title">Methods</h2><div id="__sec9" class="sec sec-first"><h3>Study design and treatments</h3><p id="__p19" class="p p-first">This study was an open-label, four-period, fixed-sequence trial performed in healthy male and female subjects to investigate the relative bioavailability of dabigatran etexilate given as single doses, either alone or after multiple doses of rifampicin, or after cessation of rifampicin. Twenty-four subjects were to be enrolled, with at least eight of each sex. The trial was conducted at CRS Clinical Research Services Mannheim GmbH (Mannheim, Germany) in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Harmonised Tripartite Guideline for Good Clinical Practice (GCP), after approval by the local independent ethics committee (IEC). The trial was sponsored by Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Ingelheim, Germany.</p><p id="__p20">Dabigatran etexilate (Pradaxa®; Boehringer Ingelheim Pharma GmbH &amp; Co. KG) was administered as 150 mg hydroxypropyl methylcellulose capsules. Rifampicin was administered as the commercially available Rifa® 600 mg coated tablets (Grünenthal GmbH, Aachen, Germany).</p><p id="__p21">The subjects received single oral doses of dabigatran etexilate (150 mg), always in the morning at 08.00 h, during the following four treatment periods (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/figure/fig01/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob="ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>): period 1 (treatment A), dabigatran etexilate 150 mg administered on day 1 (reference); period 2 (treatment B), rifampicin 600 mg once daily administered for 7 days (days 2–8) in the evening at 20.00 h, with the last dose of rifampicin given 12 h before dabigatran etexilate 150 mg administered on day 9 (test 1); period 3 (treatment C), a single dose of dabigatran etexilate 150 mg administered on day 16 after 7 days of rifampicin washout (test 2); and period 4 (treatment D), a single dose of dabigatran etexilate 150 mg administered on day 23 after 14 days of rifampicin washout (test 3).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01" co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/figure/fig01/" target="figure" rid-figpopup="fig01" rid-ob="ob-fig01"><img src="./PMC3477350_files/bcp0074-0490-f1.gif" class="small-thumb" alt="Figure 1" title="Figure 1" src-large="/pmc/articles/PMC3477350/bin/bcp0074-0490-f1.jpg"></a><div class="icnblk_cntnt" id="lgnd_fig01"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/figure/fig01/" target="figure" rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div><!--caption a4--><div><span>Administration of trial medication (upper half of the diagram) and definition of treatment periods for safety analyses (lower half of the diagram). Dabigatran etexilate was always given in the morning at 08.00 h. Rifampicin was always administered in</span> <strong>...</strong></div></div></div><p id="__p23" class="p p-last">A screening examination (visit 1) was performed between days −21 and −1. Washout periods between subsequent dabigatran etexilate doses were included between the study days (days 1, 9, 16 and 23). The end-of-trial examination was scheduled between days 25 and 28 (time window).</p></div><div id="__sec10" class="sec"><h3>Subjects</h3><p id="__p24" class="p p-first">Healthy male and female subjects [based upon complete medical history, physical examination, vital signs (blood pressure and pulse rate), 12-lead electrocardiogram (ECG), clinical and laboratory tests], aged ≥18–45 years, with a body mass index between ≥18.5 and ≤29.9 kg m<sup>−2</sup>, were included in the trial. Participants gave their written informed consent in accordance with GCP and local legislation.</p><p id="__p25" class="p p-last">The exclusion criteria included any of the following: gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders, risk of bleeding, previous use of rifampicin or other P-gp or CYP450 inhibitors/inducers within 4 weeks prior to the start of treatment.</p></div><div id="__sec11" class="sec"><h3>Study end-points</h3><p id="__p26" class="p p-first">The primary PK end-points were area under the concentration–time curve (AUC<sub>0–∞</sub>) and maximal plasma concentration (<em>C</em><sub>max</sub>) of total dabigatran (free plus conjugated). The primary comparison was between treatment B (single dose of dabigatran etexilate 150 mg after multiple doses of rifampicin 600 mg) <em>vs.</em> reference treatment A (single dose of dabigatran etexilate 150 mg before any rifampicin treatment), with α-adjustment of the 90% confidence intervals (CIs) of AUC<sub>0–∞</sub> and <em>C</em><sub>max</sub> to account for multiple testing of two correlated primary end-points [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b22" rid="b22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079383" role="button" aria-expanded="false" aria-haspopup="true">22</a>].</p><p id="__p27">Further comparisons were performed between treatment C (single dose of dabigatran etexilate 150 mg after 7 days of washout since last intake of rifampicin 600 mg) and reference treatment A, and between treatment D (single dose of dabigatran etexilate 150 mg after 14 days washout after the last intake of rifampicin 600 mg) and reference treatment A.</p><p id="__p28" class="p p-last">The secondary PK end-points included AUC<sub>0–∞</sub> and <em>C</em><sub>max</sub> of free dabigatran, and <em>C</em><sub>max</sub> and time from dosing to maximal plasma concentration (<em>t</em><sub>max</sub>) of total dabigatran. The ratio of urinary concentrations of 6β-hydroxycortisol to cortisol as a marker of induction of CYP3A4 by rifampicin and an evaluation of safety were other secondary end-points.</p></div><div id="__sec12" class="sec"><h3>Pharmacokinetic determinations</h3><p id="__p29" class="p p-first">Blood samples for dabigatran PK measurements were collected before (−0.5 h) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 h after administration of a single dose of 150 mg dabigatran etexilate in each treatment period. Plasma concentrations of free, nonconjugated dabigatran, total dabigatran [sum of free and conjugated dabigatran (measured after alkaline cleavage of conjugates)], the prodrug, dabigatran etexilate, and the intermediate metabolites, BIBR 1087 SE and BIBR 951 BS, were determined by a validated high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method at AAI Pharma Deutschland GmbH &amp; Co. KG, Neu-Ulm, Germany.</p><p id="__p30">Briefly, plasma was prepared from EDTA blood (at 2000g–4000g for 10 minutes); for the determination of free dabigatran, 50 µl of plasma was aliquoted, diluted with 50 µl 0.2 <span class="small-caps">m</span> ammonium formate buffer (pH 3.5), spiked with 40 µl internal standard solution (100 ng ml<sup>−1</sup>[<sup>13</sup>C<sub>6</sub>]dabigatran), mixed and centrifuged. For the determination of total dabigatran, 50 µl of plasma was aliquoted, spiked with 40 µl internal standard solution and mixed with 20 µl 0.2 <span class="small-caps">m</span> sodium hydroxide. After 2 h of incubation at 37°C, the samples were acidified with 30 µl 0.2 <span class="small-caps">m</span> hydrochloric acid, mixed and then centrifuged.</p><p id="__p31">For each determination, an aliquot of the resulting supernatant was transferred into autosampler vials. The analytes were extracted by column switching and were chromatographed on an analytical C18 reversed phase HPLC column with gradient elution.</p><p id="__p32">The lowest limit of quantification of free or total dabigatran was 1 ng ml<sup>−1</sup>, the inaccuracy was at maximum −5.37% (at 3 ng ml<sup>−1</sup> nominal dabigatran concentration), and the imprecision was always &lt;9%. The limit of quantification was also 1 ng ml<sup>−1</sup> for the prodrug (dabigatran etexilate) and the intermediate metabolites, BIBR 1087 SE and BIBR 951 BS. The inaccuracy was highest with BIBR 1087 SE (–16.23 and −7.75% at 3 and 9 ng ml<sup>−1</sup> spike concentrations, respectively); imprecision was always &lt;10%.</p><p id="__p33">In addition, total dabigatran urine concentrations were measured. The calibration range was between 20 and 1000 ng ml<sup>−1</sup>, and the analyses were performed with high accuracy (inaccuracy &lt;2%) and precision (imprecision &lt;7%).</p><p id="__p34">The 6β-hydroxycortisol/cortisol ratio, an established marker of human hepatic CYP450 3A induction (but not a marker for P-gp activity), was assessed in morning spot urine samples collected within 4 h after the complete first morning voids, but before drug administration at the latest (typically 30 min before). Samples were taken in the morning after subjects had received three doses of rifampicin during treatment B and before administration of dabigatran in each respective treatment period. Thus, morning spot urine samples were collected at baseline, day 1 (period 1), days 5 and 9 (period 2), day 16 (period 3) and day 23 (period 4).</p><p id="__p35" class="p p-last">Urinary concentrations of cortisol and 6β-hydroxycortisol were analysed by an HPLC-MS/MS method at SGS Cephac Europe, St Benoît, France. The calibration curves for 6β-hydroxycortisol and cortisol ranged between 1–1000 and 10–3000 ng ml<sup>−1</sup>, respectively. The assay had a low interday inaccuracy and imprecision of &lt;11 (6β-hydroxycortisol) and 13% (cortisol) at all spiked concentrations. Induction of CYP3A by rifampicin was assessed by the change in the ratio of 6β-hydroxycortisol/cortisol after a 7 day treatment of 600 mg rifampicin once daily and after cessation of rifampicin, compared with the ratio at baseline before the administration of rifampicin.</p></div><div id="__sec13" class="sec"><h3>Safety</h3><p id="__p36" class="p p-first-last">Safety was assessed by medical examination, pulse rate, blood pressure, 12-lead ECG, laboratory parameters, and the occurrence and severity of adverse events (AEs). The investigator assessed tolerability based on AEs and the laboratory evaluation according to the categories ‘good’, ‘satisfactory’, ‘not satisfactory’ and ‘bad’.</p></div><div id="__sec14" class="sec sec-last"><h3>Statistical methods</h3><p id="__p37" class="p p-first-last">Point estimators (geometric means; gMeans) of the median intrasubject ratios of AUC<sub>0–∞</sub> and <em>C</em><sub>max</sub> were calculated. The statistical model was an analysis of variance model on log-transformed parameters, including effects for ‘subject’ and ‘treatment’. However, a confidence interval for the relative bioavailability that does not contain the value 100% is equivalent to an effect significantly different from zero. Confidence intervals were based on the residual error from the investigated treatment comparison. Descriptive statistics for all other parameters were calculated.</p></div></div><div id="__sec15" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-13"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-14">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec15title">Results</h2><div id="__sec16" class="sec sec-first"><h3>Study population</h3><p id="__p38" class="p p-first-last">A total of 24 healthy volunteers entered the study and were treated; 10 (41.7%) were male and 14 (58.3%) female. All subjects were Caucasian. Their mean age was 32.9 years (range 22–44 years), with a mean body mass index of 25.1 kg m<sup>−2</sup>. Two subjects discontinued treatment prematurely (withdrew consent due to personal reasons); however, these subjects underwent the end-of-trial visit. The 22 subjects who completed treatment as planned received dabigatran etexilate 150 mg for 4 days (1 day in each treatment period) and rifampicin 600 mg for 7 days (period 2); the other two subjects received dabigatran etexilate 150 mg for 2 days (1 day in the first two treatment periods) and rifampicin 600 mg for 7 days (period 2).</p></div><div id="__sec17" class="sec"><h3>Pharmacokinetic parameters</h3><p id="__p39" class="p p-first">The shapes of the plasma concentration–time profiles of free and total dabigatran were highly comparable, as shown in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/figure/fig02/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob="ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>. The PK parameters of total dabigatran after administration of dabigatran etexilate 150 mg, with and without rifampicin, are shown in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/table/tbl1/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="fig02" co-legend-rid="lgnd_fig02"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/figure/fig02/" target="figure" rid-figpopup="fig02" rid-ob="ob-fig02"><img src="./PMC3477350_files/bcp0074-0490-f2.gif" class="small-thumb" alt="Figure 2" title="Figure 2" src-large="/pmc/articles/PMC3477350/bin/bcp0074-0490-f2.jpg"></a><div class="icnblk_cntnt" id="lgnd_fig02"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/figure/fig02/" target="figure" rid-figpopup="fig02" rid-ob="ob-fig02">Figure 2</a></div><!--caption a4--><div><span>Geometric mean (gMean) plasma concentration–time profiles (semi-logarithmic scale) of total (a) and free dabigatran (b) after a single oral dose of 150 mg dabigatran etexilate on day 1 (reference; treatment A), on day 9 after administration of</span> <strong>...</strong></div></div></div><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl1"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/table/tbl1/" target="table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class="table img_link icnblk_img figpopup"><img alt="Table 1" title="Table 1" class="small-thumb" src="./PMC3477350_files/saved_resource" src-large="/pmc/articles/PMC3477350/table/tbl1/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/table/tbl1/" target="table" rid-figpopup="tbl1" rid-ob="ob-tbl1">Table 1</a></div><!--caption a4--><div><span>Pharmacokinetic parameters of total dabigatran after administration of dabigatran etexilate 150 mg, with and without rifampicin</span></div></div></div><p id="__p43">Relative to the reference treatment (dabigatran etexilate alone), the administration of the P-gp inducer, rifampicin, over 7 days (treatment B) resulted in a significant reduction in the exposure to total dabigatran (67% reduction in AUC<sub>0–∞</sub> and 65.5% reduction in <em>C</em><sub>max</sub>) on day 9 (treatment B) in comparison with day 1 (treatment A; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/table/tbl2/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). The gMean ratio for the primary comparison was 33.0% (90% CI 26.5, 41.2%) for the AUC<sub>0–∞</sub> and 34.5% (90% CI 26.9, 44.1%) for the <em>C</em><sub>max</sub>. After adjustment of the CIs for multiple comparisons, the lower and upper limit of the CIs were 25.9 and 42.1%, respectively, for the AUC<sub>0–∞</sub>, and 26.2 and 45.2%, respectively, for <em>C</em><sub>max</sub>. Results indicated a statistically significant (<em>P</em> &lt; 0.05) effect of rifampicin on the total dabigatran exposure.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl2"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/table/tbl2/" target="table" rid-ob="ob-tbl2" rid-figpopup="tbl2" class="table img_link icnblk_img figpopup"><img alt="Table 2" title="Table 2" class="small-thumb" src="./PMC3477350_files/saved_resource(1)" src-large="/pmc/articles/PMC3477350/table/tbl2/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/table/tbl2/" target="table" rid-figpopup="tbl2" rid-ob="ob-tbl2">Table 2</a></div><!--caption a4--><div><span>Geometric means (gMeans) and relative bioavailability for intra-individual comparisons of a single dose of dabigatran etexilate 150 mg given alone (reference; treatment A) and after administration of multiple doses of rifampicin (test 1; treatment B)</span></div></div></div><p id="__p46">The time to peak (<em>t</em><sub>max</sub>) and the terminal half-life (<em>t</em><sub>1/2</sub>) were not affected by rifampicin administration. The <em>t</em><sub>max</sub>, <em>t</em><sub>1/2</sub>, mean residence time after oral administration values and the shape of the plasma concentration–time curve were similar between treatments A and B.</p><p id="__p47">For the single dose of 150 mg dabigatran etexilate after a 7 day washout after the last dose of rifampicin (treatment C, day 16), AUC<sub>0–∞</sub> and <em>C</em><sub>max</sub> values were reduced by 18 and 20%, respectively, compared with the reference, treatment A. The gMean ratio of treatment C and the reference treatment was 82.3% (90% CI 65.3, 103.9%) for the AUC<sub>0–∞</sub> and 81.4% (90% CI 65.2, 101.5%) for <em>C</em><sub>max</sub>. Fourteen days after the last administration of rifampicin (treatment D, day 23), the AUC<sub>0–∞</sub> and <em>C</em><sub>max</sub> values were reduced by 15 and 20%, respectively, compared with the reference. The gMean ratio of treatment D and the reference treatment was 85.7% (90% CI 67.7, 108.5%) for the AUC<sub>0–∞</sub> and 81.6% (90% CI 63.1, 105.6%) for <em>C</em><sub>max</sub>. Intra-individual comparisons of the exposure parameters, AUC<sub>0–∞</sub> and <em>C</em><sub>max</sub>, between all treatments are shown in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/figure/fig03/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig03" rid-ob="ob-fig03" co-legend-rid="lgnd_fig03"><span>Figure 3</span></a>.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="fig03" co-legend-rid="lgnd_fig03"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/figure/fig03/" target="figure" rid-figpopup="fig03" rid-ob="ob-fig03"><img src="./PMC3477350_files/bcp0074-0490-f3.gif" class="small-thumb" alt="Figure 3" title="Figure 3" src-large="/pmc/articles/PMC3477350/bin/bcp0074-0490-f3.jpg"></a><div class="icnblk_cntnt" id="lgnd_fig03"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/figure/fig03/" target="figure" rid-figpopup="fig03" rid-ob="ob-fig03">Figure 3</a></div><!--caption a4--><div><span>Intra-individual comparisons of AUC<sub>0–∞</sub> (upper panel) and <em>C</em><sub>max</sub> (lower panel) of total dabigatran after a single oral dose of 150 mg dabigatran etexilate alone on day 1 (treatment A) or 1, 7 or 14 days after the last administration of rifampicin</span> <strong>...</strong></div></div></div><p id="__p49">For reference treatment A (day 1), male subjects had approximately 76% of the AUC<sub>0–∞</sub> and 67% of the <em>C</em><sub>max</sub> of female subjects in the trial. Following the administration of rifampicin over 7 days, the reduction in total dabigatran exposure was similar in male and female subjects.</p><p id="__p50" class="p">The PK parameters of free dabigatran followed the same trend as those of total dabigatran (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/figure/fig02/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob="ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2b</span></a>), and the ratio between total and free dabigatran AUC<sub>0–∞</sub> was not modulated by rifampicin administration. Furthermore, the prodrug (dabigatran etexilate) and the intermediate metabolites (BIBR 951 BS and BIBR 1087 SE) were affected in the same way as dabigatran (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/table/tbl3/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl3" rid-ob="ob-tbl3" co-legend-rid=""><span>Table 3</span></a>). As the concentrations (only <em>C</em><sub>max</sub> could be evaluated) were already rather small in the reference treatment, no quantitative assessment of the extent of reduction was feasible.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl3"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/table/tbl3/" target="table" rid-ob="ob-tbl3" rid-figpopup="tbl3" class="table img_link icnblk_img figpopup"><img alt="Table 3" title="Table 3" class="small-thumb" src="./PMC3477350_files/saved_resource(2)" src-large="/pmc/articles/PMC3477350/table/tbl3/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/table/tbl3/" target="table" rid-figpopup="tbl3" rid-ob="ob-tbl3">Table 3</a></div><!--caption a4--><div><span>Pharmacokinetic parameters of prodrug (dabigatran etexilate) and intermediate metabolites (BIBR 1087 SE and BIBR 951 BS) after administration of dabigatran etexilate 150 mg, with and without rifampicin</span></div></div></div></div><div id="__sec18" class="sec"><h3>6β-Hydroxycortisol/cortisol urine ratios</h3><p id="__p53" class="p p-first-last">Compared with day 1, the urinary 6β-hydroxycortisol/cortisol ratio on day 9 was increased approximately 5.6-fold, from a gMean (gCV %) 6β-hydroxycortisol/cortisol ratio of 3.92 (65.3) to 22.0 (48.5), indicating CYP450 3A induction as a result of rifampicin administration. The urinary 6β-hydroxycortisol/cortisol ratio was still slightly elevated on day 16 (∼1.2-fold), but had returned to baseline by day 23, 2 weeks after the end of treatment with rifampicin.</p></div><div id="__sec19" class="sec sec-last"><h3>Safety</h3><p id="__p54" class="p p-first">All 24 subjects who received at least one dose of study drug were included in the safety evaluation.</p><p id="__p55">Only two (8.3%) subjects reported any AEs during treatment with dabigatran etexilate alone, four (16.7%) subjects during treatment with dabigatran etexilate plus rifampicin and two (8.3%) subjects during treatment with rifampicin alone (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/table/tbl4/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob="ob-tbl4" co-legend-rid=""><span>Table 4</span></a>). In addition, one subject (4.5%; 1 of 22) reported an AE during the washout period after treatment period 3.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl4"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/table/tbl4/" target="table" rid-ob="ob-tbl4" rid-figpopup="tbl4" class="table img_link icnblk_img figpopup"><img alt="Table 4" title="Table 4" class="small-thumb" src="./PMC3477350_files/saved_resource(3)" src-large="/pmc/articles/PMC3477350/table/tbl4/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/table/tbl4/" target="table" rid-figpopup="tbl4" rid-ob="ob-tbl4">Table 4</a></div><!--caption a4--><div><span>Number (%) of subjects with adverse events reported during treatment with dabigatran etexilate (excluding washout periods)</span></div></div></div><p id="__p58">The most frequently reported AEs were nervous system disorders, with headache the most common (dabigatran, two subjects; rifampicin, one subject; and dabigatran plus rifampicin, three subjects). No other AEs were reported during treatment with dabigatran alone. Other AEs reported were vertigo and hyperhidrosis (one subject each) during the dabigatran plus rifampicin period; dizziness, nausea, oropharyngeal pain, vomiting and fatigue (one subject each) during the rifampicin alone period; and nausea (one subject) during the washout after period 3.</p><p id="__p59">All AEs were of mild or moderate intensity and resolved by the end of the trial. There were no deaths, other serious AEs, other significant AEs, severe AEs or AEs that led to discontinuation of study treatment.</p><p id="__p60" class="p p-last">Vital signs, ECG and safety laboratory assessments did not indicate any relevant, consistent or treatment-related untoward reactions. Global clinical tolerability was good in all subjects.</p></div></div><div id="__sec20" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-15"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-16">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec20title">Discussion</h2><p id="__p61" class="p p-first">Preclinical investigations have shown that dabigatran etexilate (but not dabigatran or its intermediate metabolites) is a substrate for the efflux transporter protein P-gp. Previous investigations suggest that the bioavailability of dabigatran may be affected by P-gp inhibitors [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b23" rid="b23" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">23</a>]. In this study, a 1 week course of rifampicin, a potent inducer of P-gp, decreased exposure to dabigatran by 67%.</p><p id="__p62">The approved dabigatran etexilate dose for stroke prevention in patients with atrial fibrillation is 150 mg twice daily for most patients [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b7" rid="b7" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">7</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b8" rid="b8" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">8</a>]. The present study investigated dabigatran etexilate 150 mg with or without rifampicin 600 mg once daily. These doses were selected because they reflected standard clinical doses, and the plasma concentrations of dabigatran and rifampicin in this trial represent clinically relevant drug exposure. The selected dosing regimen for rifampicin (7 day treatment with cessation of treatment the evening, i.e. 12 h, before administration of dabigatran etexilate) allowed for a test of maximal induction of P-gp without interference of inhibiting effects, because rifampicin was stopped after the last dose given in the evening before dabigatran administration. A single dose of dabigatran etexilate was considered to be representative of the effect following multiple dosing, potentially overestimating, rather than underestimating, the effect. In conclusion, the selected doses were expected to allow adequate determination of the PK parameters of dabigatran after P-gp induction.</p><p id="__p63">In this study, the administration of rifampicin for 7 days resulted in a significant and relevant reduction in the bioavailability of total dabigatran (67 and 65.5% reduction in AUC<sub>0–∞</sub> and <em>C</em><sub>max</sub> values of total dabigatran, respectively) after administering a single oral dose of 150 mg dabigatran etexilate in healthy volunteers. Within 7 days following the cessation of rifampicin administration, the bioavailability of total dabigatran returned almost to baseline values. Pharmacokinetic parameters of free dabigatran were influenced in a similar fashion.</p><p id="__p64">In the present trial, rifampicin administration also induced CYP3A, as shown by an elevated urinary 6β-hydroxycortisol/cortisol ratio [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b24" rid="b24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079368" role="button" aria-expanded="false" aria-haspopup="true">24</a>]. Such induction has been documented to dissipate in about 2 weeks after discontinuation of rifampicin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b25" rid="b25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079384" role="button" aria-expanded="false" aria-haspopup="true">25</a>]. Indeed, in this trial, the urinary 6β-hydroxycortisol/cortisol ratio was found to be only 1.2-fold higher than baseline values after 1 week and had returned to baseline levels 2 weeks after discontinuation of treatment with rifampicin. The effect on dabigatran was highly comparable, which seems physiologically reasonable because both CYP3A4 and P-gp share the same induction pathway via the transcription factor pregnane X receptor [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b26" rid="b26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079376" role="button" aria-expanded="false" aria-haspopup="true">26</a>].</p><p id="__p65">The reduction of the total dabigatran exposure after rifampicin pretreatment seen in this trial was of similar magnitude or only slightly exceeded the effects reported for digoxin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b27" rid="b27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079365" role="button" aria-expanded="false" aria-haspopup="true">27</a>], a prototypical P-gp substrate, or aliskiren [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b28" rid="b28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079380" role="button" aria-expanded="false" aria-haspopup="true">28</a>]. Interestingly, despite a 56% reduction in the AUC<sub>0–∞</sub> of aliskiren or a 58% reduction in <em>C</em><sub>max</sub> of digoxin after rifampicin treatment, the renal clearance and half-life of these drugs always remained unaffected [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b27" rid="b27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079382" role="button" aria-expanded="false" aria-haspopup="true">27</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b28" rid="b28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079385" role="button" aria-expanded="false" aria-haspopup="true">28</a>]. This is in perfect agreement with the results reported in this study for dabigatran.</p><p id="__p66">Dabigatran etexilate is assumed to be absorbed mainly in the duodenum. The pronounced effect of rifampicin on dabigatran kinetics might, thus, be due to a remarkable increase in duodenal P-gp expression (about a threefold increase) after rifampicin, as reported <em>ex vivo</em>[<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b27" rid="b27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079374" role="button" aria-expanded="false" aria-haspopup="true">27</a>] and <em>in vitro</em>[<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b26" rid="b26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079363" role="button" aria-expanded="false" aria-haspopup="true">26</a>]. An approximately 66% reduction in bioavailability by P-gp induction may be physiologically plausible for dabigatran etexilate, whose absorption (besides solubility limitations) is solely dependent on the efflux transporter P-gp. Moreover, recent <em>in vitro</em> data have clearly demonstrated that dabigatran has no affinity to any efflux (P-gp, BCRP and MRP2) or uptake transporter (OAT1, OAT3, OATP1B1, OATP1B3, OATP2B1, OCT1 and OCT2), and that among intestinal transporters, P-gp only recognized dabigatran etexilate as substrate [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b29" rid="b29" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">29</a>]. The reduced bioavailability of dabigatran after P-gp induction contrasts with the effect observed (an increase in exposure) when dabigatran is administered with a P-gp inhibitor. For example, the administration of the strong P-gp inhibitor ketoconazole increased the AUC<sub>0–∞</sub> and <em>C</em><sub>max</sub> of dabigatran by approximately 150% compared with dabigatran alone [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b23" rid="b23" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">23</a>].</p><p id="__p67">In the present trial, male subjects receiving reference treatment A on day 1 had approximately 76% of the AUC<sub>0–∞</sub> and 67% of the <em>C</em><sub>max</sub> values of the female subjects investigated. Although there were sex differences in exposure to total dabigatran, administration of rifampicin for 7 days resulted in a similar percentage reduction in total dabigatran exposure for male and female subjects.</p><p id="__p68">The overall safety profile of all treatments was favourable. Dabigatran etexilate was well tolerated when given alone and in combination with rifampicin. The results were in line with the known safety profile of dabigatran etexilate.</p><p id="__p69">A reduction of two-thirds in dabigatran exposure due to a 1 week course of rifampicin has clinically relevant consequences. Patients undergoing orthopaedic surgery who receive dabigatran etexilate for the prevention of venous thromboembolism may not achieve therapeutic concentrations of dabigatran if they have received rifampicin immediately before surgery. Dabigatran etexilate is also indicated for stroke prevention in patients with atrial fibrillation. As a dose–response in stroke reduction has been demonstrated for dabigatran etexilate [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b13" rid="b13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079366" role="button" aria-expanded="false" aria-haspopup="true">13</a>], the significant decrease in dabigatran exposure observed with rifampicin is likely to decrease the potential for stroke prevention. Concomitant treatment with rifampicin and dabigatran should be avoided in these patients. The effect of concomitant administration of dabigatran etexilate with other P-gp inducers, such as carbamazepine, diphenylhydantoin and St John's wort has not been tested. However, it should be emphasized that vitamin K antagonists, such as warfarin, show comparable liabilities when coadministered with compounds increasing warfarin clearance, such as carbamazepine, barbiturates, rifampicin and chronic alcohol [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b30" rid="b30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079367" role="button" aria-expanded="false" aria-haspopup="true">30</a>]. Furthermore, the new factor Xa inhibitors rivaroxaban and apixaban are expected to be affected by inducers of the rifampicin type because their clearance is dependent to a large extent on CYP3A4 and partly also on P-gp [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b18" rid="b18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079371" role="button" aria-expanded="false" aria-haspopup="true">18</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b31" rid="b31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_277079381" role="button" aria-expanded="false" aria-haspopup="true">31</a>].</p><p id="__p70" class="p p-last">In summary, the administration of rifampicin, a P-gp inducer, for 7 days resulted in a statistically significant and potentially clinically relevant reduction in the bioavailability of a single oral dose of dabigatran etexilate in healthy volunteers. Within 7 days following the cessation of rifampicin administration, the bioavailability returned almost to baseline values. Owing to the potential for reduced systemic exposure to dabigatran, rifampicin and other P-gp inducers (e.g. carbamazepine and St John's wort) are not recommended for use with dabigatran etexilate [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b32" rid="b32" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">32</a>].</p></div><div id="__ackid447454" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-17"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-18">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ackid447454title">Acknowledgments</h2><div class="sec"><p id="__p71">The study was exclusively sponsored by Boehringer Ingelheim Pharma GmbH &amp; Co. KG. The study was conducted at CRS Clinical Research Services Mannheim GmbH (principal investigator: Wolfgang Timmer) under the responsibility of the sponsor, Boehringer Ingelheim, Pharma GmbH &amp; Co. KG. Writing and editorial support was provided by PAREXEL MMS and was funded by Boehringer Ingelheim. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) and were fully responsible for all content and editorial decisions, and were involved at all stages of manuscript development.</p></div></div><div id="__sec21" class="tsec bk-sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-19"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-20">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec21title">Competing Interests</h2><!--/article/back/sec/--><p id="__p72" class="p p-first-last">SH, MK-B, AS, GN, UL and PAR are employees of Boehringer Ingelheim.</p></div><div id="__ref-listid419195" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-21"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-22">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ref-listid419195title">REFERENCES</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="b1">1. <span class="element-citation">Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, Rathgen K, Svärd R. Pharmacokinetic profile of the oral direct thrombin inhibitor dabagitran etexilate in healthy volunteers and patients undergoing total hip replacement. <span><span class="ref-journal">J Clin Pharmacol. </span>2005;<span class="ref-vol">45</span>:555–63.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15831779" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b2">2. <span class="element-citation">Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. <span><span class="ref-journal">Drug Metab Dispos. </span>2008;<span class="ref-vol">36</span>:386–99.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18006647" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b3">3. <span class="element-citation">Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran, a new oral direct thrombin inhibitor in healthy male subjects. <span><span class="ref-journal">Br J Clin Pharmacol. </span>2007;<span class="ref-vol">64</span>:292–303.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2000643/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17506785" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b4">4. <span class="element-citation">Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. <span><span class="ref-journal">Clin Pharmacokinet. </span>2008;<span class="ref-vol">47</span>:285–95.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18399711" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b5">5. <span class="element-citation">Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. <span><span class="ref-journal">Clin Pharmacokinet. </span>2008;<span class="ref-vol">47</span>:47–59.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18076218" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b6">6. <span class="element-citation">Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. <span><span class="ref-journal">Clin Pharmacokinet. </span>2010;<span class="ref-vol">49</span>:259–68.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20214409" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b7">7. <span class="element-citation">Boehringer Ingelheim, Burlington, ON. <span class="ref-journal">Pradax™ Product Monograph [Internet]</span> 2012.  Available at  <a href="http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&amp;code=84384" ref="reftype=extlink&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&amp;code=84384</a> (last accessed 28 February 2012)</span></div><div class="ref-cit-blk half_rhythm" id="b8">8. <span class="element-citation">FDA [Internet] Pradaxa label. 2010.  Available at  <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022512s000lbl.pdf" ref="reftype=extlink&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022512s000lbl.pdf</a> (last accessed 6 April 2011)</span></div><div class="ref-cit-blk half_rhythm" id="b9">9. <span class="element-citation">Biotech Pharma News [Internet] Boehringer Ingelheim: PRAZAXA (dabigatran etexilate) approved in Japan for stroke prevention in atrial fibrillation. 2011.  Available at  <a href="http://www.biotechpharmanews.com/news/37-jan-2011/634-boehringer-ingelheim-prazaxa-dabigatran-etexilate-approved-in-japan-for-stroke-prevention-in-atrial-fibrillation.html" ref="reftype=extlink&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://www.biotechpharmanews.com/news/37-jan-2011/634-boehringer-ingelheim-prazaxa-dabigatran-etexilate-approved-in-japan-for-stroke-prevention-in-atrial-fibrillation.html</a> (last accessed 28 February 2012)</span></div><div class="ref-cit-blk half_rhythm" id="b10">10. <span class="element-citation">Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR. (RE-MODEL Study Group) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. <span><span class="ref-journal">J Thromb Haemost. </span>2007;<span class="ref-vol">5</span>:2178–85.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17764540" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b11">11. <span class="element-citation">Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiaracchi R, Hantel S, Schnee J, Büller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. <span><span class="ref-journal">Lancet. </span>2007;<span class="ref-vol">370</span>:949–56.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17869635" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b12">12. <span class="element-citation">Eriksson B, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR. (RE-NOVATE Study Group) for the RE-NOVATE II Study Group: oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) <span><span class="ref-journal">Thromb Haemost. </span>2011;<span class="ref-vol">105</span>:721–9.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/21225098" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b13">13. <span class="element-citation">Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. (RE-LY Steering Committee and Investigators) Dabigatran versus warfarin in patients with atrial fibrillation. <span><span class="ref-journal">N Engl J Med. </span>2009;<span class="ref-vol">361</span>:1139–51.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19717844" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b14">14. <span class="element-citation">Stangier J, Stähle H, Rathgen K, Reseski K, Kornicke T. Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug. <span><span class="ref-journal">J Thromb Haemost. </span>2007;<span class="ref-vol">5</span>(Suppl. 2)</span> Abstract P-W-677.</span></div><div class="ref-cit-blk half_rhythm" id="b15">15. <span class="element-citation">Stangier J, Stähle H, Rathgen K, Reseski K, Körnicke T. No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin. <span><span class="ref-journal">J Thromb Haemost. </span>2007;<span class="ref-vol">5</span>(Suppl. 2)</span> Abstract P-W-672.</span></div><div class="ref-cit-blk half_rhythm" id="b16">16. <span class="element-citation">Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. <span><span class="ref-journal">Am J Cardiovasc Drugs. </span>2009;<span class="ref-vol">9</span>:59–68.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19178132" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b17">17. <span class="element-citation">Boehringer Ingelheim, Ridgefield, CT. Pradaxa® US prescribing information [Internet] 2012.  Available at  <a href="http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&amp;folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf" ref="reftype=extlink&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&amp;folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf</a> (last accessed 28 February 2012)</span></div><div class="ref-cit-blk half_rhythm" id="b18">18. <span class="element-citation">Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. <span><span class="ref-journal">Thromb Haemost. </span>2010;<span class="ref-vol">103</span>:572–85.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20135071" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b19">19. <span class="element-citation">Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. <span><span class="ref-journal">Clin Pharmacol Ther. </span>1996;<span class="ref-vol">59</span>:7–13.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8549036" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b20">20. <span class="element-citation">Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. <span><span class="ref-journal">Eur J Clin Pharmacol. </span>1998;<span class="ref-vol">54</span>:53–8.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9591931" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b21">21. <span class="element-citation">Galteau MM, Shamsa F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. <span><span class="ref-journal">Eur J Clin Pharmacol. </span>2003;<span class="ref-vol">59</span>:713–33.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14605790" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b22">22. <span class="element-citation">Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials. <span><span class="ref-journal">Biometrics. </span>1987;<span class="ref-vol">43</span>:487–98.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/3663814" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b23">23. <span class="element-citation">Advisory Committee Briefing Document [Internet] Dabigatran etexilate. 2010.  Boehringer Ingelheim; Available at  <a href="http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf" ref="reftype=extlink&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf</a> (last accessed 4 April 2011)</span></div><div class="ref-cit-blk half_rhythm" id="b24">24. <span class="element-citation">Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, Martin DE. Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP3A4 induction. <span><span class="ref-journal">J Clin Pharmacol. </span>1999;<span class="ref-vol">39</span>:487–94.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10234596" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b25">25. <span class="element-citation">Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. <span><span class="ref-journal">Clin Pharmacokinet. </span>2003;<span class="ref-vol">42</span>:819–50.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12882588" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b26">26. <span class="element-citation">Gupta A, Mugundu GM, Desai PB, Thummel KE, Unadkat JD. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. <span><span class="ref-journal">Drug Metab Dispos. </span>2008;<span class="ref-vol">36</span>:1172–80.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18332086" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b27">27. <span class="element-citation">Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. <span><span class="ref-journal">J Clin Invest. </span>1999;<span class="ref-vol">104</span>:147–53.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC408477/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10411543" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b28">28. <span class="element-citation">Tapaninen T, Neuvonen PJ, Niemi M. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. <span><span class="ref-journal">Eur J Clin Pharmacol. </span>2010;<span class="ref-vol">66</span>:497–502.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20179914" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b29">29. <span class="element-citation">Kishimoto W, Ishiguro N, Saito A, Ebner T, Haertter S, Igarashi T. Characterization of drug transporters involved in the disposition of dabigatran etexilate and its active form, dabigatran. 9th Int Mtg Int Soc Study Xenobiotics (ISSX), Istanbul, 4–8 Sep 2010. <span><span class="ref-journal">Drug Metab Rev. </span>2010;<span class="ref-vol">42</span>:293.</span> Abstr P469.</span></div><div class="ref-cit-blk half_rhythm" id="b30">30. <span class="element-citation">Moualla H, Garcia D. Vitamin K antagonists – current concepts and challenges. <span><span class="ref-journal">Thromb Res. </span>2011;<span class="ref-vol">128</span>:210–15.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/21570107" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b31">31. <span class="element-citation">Deloughery TG. Practical aspects of the oral new anticoagulants. <span><span class="ref-journal">Am J Hematol. </span>2011;<span class="ref-vol">86</span>:586–90.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/21674571" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b32">32. <span class="element-citation">Boehringer Ingelheim, Ingelheim. Pradaxa® summary of product characteristics [Internet] 2011.  Available at  <a href="http://www.medicines.org.uk/emc/medicine/20760/SPC/Pradaxa+110+mg+hard+capsules" ref="reftype=extlink&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://www.medicines.org.uk/emc/medicine/20760/SPC/Pradaxa+110+mg+hard+capsules</a> (last accessed 28 February 2012)</span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#__abstractid753267title">Abstract</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#__sec7title">Introduction</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#__sec8title">Methods</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#__sec15title">Results</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#__sec20title">Discussion</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#__ackid447454title">Acknowledgments</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#__sec21title">Competing Interests</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#__ref-listid419195title">REFERENCES</a></li></ul></div></div><!--post-content--><hr class="whole_rhythm no_bottom_margin"><div class="courtesy-note no_margin small">Articles from <span class="acknowledgment-journal-title">British Journal of Clinical Pharmacology</span> are provided here courtesy of <strong>British Pharmacological Society</strong></div></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="try-button"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/?report=reader"><img src="./PMC3477350_files/3838809" alt="PubReader format: click here to try"></a></div><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/epub/">ePub (beta)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/pdf/bcp0074-0490.pdf">PDF (1.2M)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" data-citationid="PMC3477350" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3477350%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC3477350_files/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3477350%2F&amp;text=Decrease%20in%20the%20oral%20bioavailability%20of%20dabigatran%20etexilate%20after%20co-medication%20with%20rifampicin" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC3477350_files/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3477350%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC3477350_files/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="22348256" data-aiid="3477350" data-aid="3477350" data-iid="215557" data-domainid="279" data-domain="brjclinpharm" data-accid="PMC3477350" data-md5="378a9d98e4bece9b1f18f7fec2fbcbda">
<div class="portlet pubmed_favoritesad">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Save items</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="pmfavad" toggles="ui-portlet_content-25" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-25" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<input type="hidden" name="absid" id="absid" value="3477350"><div id="pubmed_favoritesad" class="empty" data-db="pmc">
<span role="menubar"><div class="ui-ncbisetswitch ltd-hover" role="menuitem" aria-expanded="false" aria-haspopup="true"><a href="http://www.ncbi.nlm.nih.gov/myncbi/collections/" class="jig-ncbisetswitch blind collink ltd-hover ui-ncbisetswitch-hasStar" id="favList" data-jigconfig="destSelector:&#39;#favUL&#39;,starExists:true,createCollectionUrl:&#39;#&#39;,manageCollectionsUrl:&#39;/myncbi/collections/&#39;"><span class="star"></span>Add to Favorites</a><a class="ui-ncbisetswitch-button ltd-hover" title="View more options" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#"><span class="ui-icon ui-icon-triangle-1-s ui-ncbisetswitch-down">View more options</span></a></div></span><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu ui-ncbisetswitch-popper"><ul id="favUL" class="ui-ncbisetswitch-options"></ul><ul class="ui-ncbisetswitch-actions"><li class="ui-ncbisetswitch-actions-create" style="display: block;"><a class="ui-ncbisetswitch-create-collection" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#">Create collection...</a></li><li class="ui-ncbisetswitch-actions-manage" style="display: block;"><a class="ui-ncbisetswitch-manage-collections" href="http://www.ncbi.nlm.nih.gov/myncbi/collections/">Manage collections...</a></li></ul></div>
</div>
<div class="colloading">loading</div>
<span id="submenu_AddToCollections"><form method="post"><input type="submit" class="button_apply" name="addtocollection" value="1"></form></span>
</div></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" toggles="ui-portlet_content-27" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-27" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/18076218" ref="reftype=relart&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.</a><span class="source">[Clin Pharmacokinet. 2008]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-29" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Stangier J, Stähle H, Rathgen K, Fuhr R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Pharmacokinet. 2008; 47(1):47-59. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/22252796" ref="reftype=relart&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.</a><span class="source">[Eur J Clin Pharmacol. 2012]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-31" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Clemens A, van Ryn J, Sennewald R, Yamamura N, Stangier J, Feuring M, Härtter S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Eur J Clin Pharmacol. 2012 May; 68(5):607-16. Epub 2012 Jan 18.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/15831779" ref="reftype=relart&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.</a><span class="source">[J Clin Pharmacol. 2005]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-33" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, Rathgen K, Svärd R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Clin Pharmacol. 2005 May; 45(5):555-63. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/18399711" ref="reftype=relart&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.</a><span class="source">[Clin Pharmacokinet. 2008]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-35" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Stangier J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Pharmacokinet. 2008; 47(5):285-95. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/20069135" ref="reftype=relart&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Dabigatran etexilate in venous thromboembolism.</a><span class="source">[Drugs Today (Barc). 2009]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-37" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ferrer E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs Today (Barc). 2009 Oct; 45(10):715-24. </em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=22348256&amp;log%24=relatedreviews&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Reviews&amp;rendering-type=normal">See reviews...</a><a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=22348256&amp;log%24=relatedarticles&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Related%20Records&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Cited by other articles in PMC</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-39" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-39" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871170/" ref="reftype=relart&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy</a><span class="source">[The Annals of Pharmacotherapy....]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-41" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Finks SW, Trujillo TC, Dobesh PP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">The Annals of Pharmacotherapy. 2016 Feb 25; 50(6)486-501</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715848/" ref="reftype=relart&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment</a><span class="source">[Journal of Thrombosis and Thro...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-43" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Journal of Thrombosis and Thrombolysis. 2016 Jan 16; 41206-232</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586008/" ref="reftype=relart&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation</a><span class="source">[American Journal of Cardiovasc...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-45" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Saliba W. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">American Journal of Cardiovascular Drugs. 2015 Jun 9; 15(5)323-335</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243910/" ref="reftype=relart&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time</a><span class="source">[British Journal of Clinical Ph...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-47" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chin PK, Wright DF, Patterson DM, Doogue MP, Begg EJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">British Journal of Clinical Pharmacology. 2014 Aug 21; 78(3)599-609</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070467/" ref="reftype=relart&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C</a><span class="source"></span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-49" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chin PK, Wright DF, Zhang M, Wallace MC, Roberts RL, Patterson DM, Jensen BP, Barclay ML, Begg EJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs in R&amp;D. 2014 May 6; 14(2)113-123</em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/citedby/" ref="reftype=relart&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|CitedBy&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Links</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-51" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-51" aria-hidden="false"><ul>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pccompound&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pccompound&amp;IdsFromResult=3477350" ref="reftype=Compound&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Compound&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Compound</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-53" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Compound<div class="brieflinkpopdesc">PubChem Compound links</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/22348256/" ref="reftype=PubMed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|PubMed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">PubMed</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-55" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">PubMed<div class="brieflinkpopdesc">PubMed citations for these articles</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pcsubstance&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pcsubstance&amp;IdsFromResult=3477350" ref="reftype=Substance&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Substance&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Substance</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-57" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Substance<div class="brieflinkpopdesc">PubChem Substance links</div>
</div>
</li>
</ul></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Recent Activity</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" toggles="ui-portlet_content-59" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-59" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="">
<div class="action">
<a href="javascript:historyDisplayState(&#39;ClearHT&#39;)">Clear</a><a href="javascript:historyDisplayState(&#39;HTOff&#39;)" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState(&#39;HTOn&#39;)" class="HTOff">Turn On</a>
</div>
<ul id="activity">
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2aa3f2911de5257e0aa0">Decrease in the oral bioavailability of dabigatran etexilate after co-medication...</a><div class="ralinkpop offscreen_noflow">Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin<div class="brieflinkpopdesc">British Journal of Clinical Pharmacology. 2012 Sep; 74(3)490</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=2" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2aa1f0c03b798175fa02">PMC3477350 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=3" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2a8cf2911de5257e06be">Case report of exercise and statin-fibrate combination therapy-caused myopathy i...</a><div class="ralinkpop offscreen_noflow">Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathways<div class="brieflinkpopdesc">BMC Research Notes. 2013; 6()52</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=4" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2a8af0c03b798175f5ee">PMC3571969 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=5" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2a2504fcfad591771d3e">Renal Failure and Rhabdomyolysis Associated With Sitagliptin and Simvastatin Use</a><div class="ralinkpop offscreen_noflow">Renal Failure and Rhabdomyolysis Associated With Sitagliptin and Simvastatin Use<div class="brieflinkpopdesc">NIHPA Author Manuscripts. 2008 Oct; 25(10)1229</div>
</div>
<div class="tertiary"></div>
</li>
</ul>
<p class="HTOn">Your browsing activity is empty.</p>
<p class="HTOff">Activity recording is turned off.</p>
<p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState(&#39;HTOn&#39;)">Turn recording back on</a></p>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/myncbi/recentactivity">See more...</a>
</div></div></div>
</div>
<div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p13" name="crb--__p13" rid="__p13" style="position: absolute; visibility: visible; width: 370px; top: 1651px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-61"><ul>
<li class="two_line" reference_id="b1">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15831779/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.</a><span class="one_line_source">[J Clin Pharmacol.  2005]</span><div class="alt-note">
<div class="authors">Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, Rathgen K, Svärd R</div>
<div class="citation">J Clin Pharmacol. 2005 May; 45(5):555-63.</div>
</div>
</li>
<li class="two_line" reference_id="b6">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/20214409/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.</a><span class="one_line_source">[Clin Pharmacokinet.  2010]</span><div class="alt-note">
<div class="authors">Stangier J, Rathgen K, Stähle H, Mazur D</div>
<div class="citation">Clin Pharmacokinet. 2010 Apr; 49(4):259-68.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p14" name="crb--__p14" rid="__p14" style="position: absolute; visibility: visible; width: 370px; top: 1788px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-62"><ul>
<li class="two_line" reference_id="b2">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18006647/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.</a><span class="one_line_source">[Drug Metab Dispos.  2008]</span><div class="alt-note">
<div class="authors">Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W</div>
<div class="citation">Drug Metab Dispos. 2008 Feb; 36(2):386-99.</div>
</div>
</li>
<li class="two_line" reference_id="b3">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17506785/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.</a><span class="one_line_source">[Br J Clin Pharmacol.  2007]</span><div class="alt-note">
<div class="authors">Stangier J, Rathgen K, Stähle H, Gansser D, Roth W</div>
<div class="citation">Br J Clin Pharmacol. 2007 Sep; 64(3):292-303.</div>
</div>
</li>
<li class="two_line" reference_id="b10" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17764540/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.</a><span class="one_line_source">[J Thromb Haemost.  2007]</span><div class="alt-note">
<div class="authors">Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR, RE-MODEL Study Group</div>
<div class="citation">J Thromb Haemost. 2007 Nov; 5(11):2178-85.</div>
</div>
</li>
<li class="two_line" reference_id="b13" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/19717844/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Dabigatran versus warfarin in patients with atrial fibrillation.</a><span class="one_line_source">[N Engl J Med.  2009]</span><div class="alt-note">
<div class="authors">Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators</div>
<div class="citation">N Engl J Med. 2009 Sep 17; 361(12):1139-51.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p15" name="crb--__p15" rid="__p15" style="position: absolute; visibility: visible; width: 370px; top: 1904px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-63"><ul>
<li class="two_line" reference_id="b2">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18006647/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.</a><span class="one_line_source">[Drug Metab Dispos.  2008]</span><div class="alt-note">
<div class="authors">Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W</div>
<div class="citation">Drug Metab Dispos. 2008 Feb; 36(2):386-99.</div>
</div>
</li>
<li class="two_line" reference_id="b16">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/19178132/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.</a><span class="one_line_source">[Am J Cardiovasc Drugs.  2009]</span><div class="alt-note">
<div class="authors">Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W</div>
<div class="citation">Am J Cardiovasc Drugs. 2009; 9(1):59-68.</div>
</div>
</li>
<li class="two_line" reference_id="b18">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/20135071/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.</a><span class="one_line_source">[Thromb Haemost.  2010]</span><div class="alt-note">
<div class="authors">Ufer M</div>
<div class="citation">Thromb Haemost. 2010 Mar; 103(3):572-85.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p16" name="crb--__p16" rid="__p16" style="position: absolute; visibility: visible; width: 370px; top: 2041px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-64"><ul>
<li class="two_line" reference_id="b19" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/8549036/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Rifampin drastically reduces plasma concentrations and effects of oral midazolam.</a><span class="one_line_source">[Clin Pharmacol Ther.  1996]</span><div class="alt-note">
<div class="authors">Backman JT, Olkkola KT, Neuvonen PJ</div>
<div class="citation">Clin Pharmacol Ther. 1996 Jan; 59(1):7-13.</div>
</div>
</li>
<li class="two_line" reference_id="b20" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9591931/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.</a><span class="one_line_source">[Eur J Clin Pharmacol.  1998]</span><div class="alt-note">
<div class="authors">Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ</div>
<div class="citation">Eur J Clin Pharmacol. 1998 Mar; 54(1):53-8.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/" class="seemore">See links ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p17" name="crb--__p17" rid="__p17" style="position: absolute; visibility: visible; width: 370px; top: 2115px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-65"><ul><li class="two_line" reference_id="b21">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/14605790/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.</a><span class="one_line_source">[Eur J Clin Pharmacol.  2003]</span><div class="alt-note">
<div class="authors">Galteau MM, Shamsa F</div>
<div class="citation">Eur J Clin Pharmacol. 2003 Dec; 59(10):713-33.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p26" name="crb--__p26" rid="__p26" style="position: absolute; visibility: visible; width: 370px; top: 3390px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-66"><ul><li class="two_line" reference_id="b22">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/3663814/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The analysis of multiple endpoints in clinical trials.</a><span class="one_line_source">[Biometrics.  1987]</span><div class="alt-note">
<div class="authors">Pocock SJ, Geller NL, Tsiatis AA</div>
<div class="citation">Biometrics. 1987 Sep; 43(3):487-98.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p64" name="crb--__p64" rid="__p64" style="position: absolute; visibility: visible; width: 370px; top: 7830px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-67"><ul>
<li class="two_line" reference_id="b24">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10234596/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction.</a><span class="one_line_source">[J Clin Pharmacol.  1999]</span><div class="alt-note">
<div class="authors">Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, Martin DE</div>
<div class="citation">J Clin Pharmacol. 1999 May; 39(5):487-94.</div>
</div>
</li>
<li class="two_line" reference_id="b25">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12882588/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Pharmacokinetic interactions with rifampicin : clinical relevance.</a><span class="one_line_source">[Clin Pharmacokinet.  2003]</span><div class="alt-note">
<div class="authors">Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT</div>
<div class="citation">Clin Pharmacokinet. 2003; 42(9):819-50.</div>
</div>
</li>
<li class="two_line" reference_id="b26">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18332086/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors.</a><span class="one_line_source">[Drug Metab Dispos.  2008]</span><div class="alt-note">
<div class="authors">Gupta A, Mugundu GM, Desai PB, Thummel KE, Unadkat JD</div>
<div class="citation">Drug Metab Dispos. 2008 Jun; 36(6):1172-80.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p65" name="crb--__p65" rid="__p65" style="position: absolute; visibility: visible; width: 370px; top: 7988px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-68"><ul>
<li class="two_line" reference_id="b27">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10411543/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.</a><span class="one_line_source">[J Clin Invest.  1999]</span><div class="alt-note">
<div class="authors">Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK</div>
<div class="citation">J Clin Invest. 1999 Jul; 104(2):147-53.</div>
</div>
</li>
<li class="two_line" reference_id="b28">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/20179914/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.</a><span class="one_line_source">[Eur J Clin Pharmacol.  2010]</span><div class="alt-note">
<div class="authors">Tapaninen T, Neuvonen PJ, Niemi M</div>
<div class="citation">Eur J Clin Pharmacol. 2010 May; 66(5):497-502.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p66" name="crb--__p66" rid="__p66" style="position: absolute; visibility: visible; width: 370px; top: 8108px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-69"><ul>
<li class="two_line" reference_id="b27">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10411543/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.</a><span class="one_line_source">[J Clin Invest.  1999]</span><div class="alt-note">
<div class="authors">Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK</div>
<div class="citation">J Clin Invest. 1999 Jul; 104(2):147-53.</div>
</div>
</li>
<li class="two_line" reference_id="b26">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18332086/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors.</a><span class="one_line_source">[Drug Metab Dispos.  2008]</span><div class="alt-note">
<div class="authors">Gupta A, Mugundu GM, Desai PB, Thummel KE, Unadkat JD</div>
<div class="citation">Drug Metab Dispos. 2008 Jun; 36(6):1172-80.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p69" name="crb--__p69" rid="__p69" style="position: absolute; visibility: visible; width: 370px; top: 8544px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-70"><ul>
<li class="two_line" reference_id="b13">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/19717844/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Dabigatran versus warfarin in patients with atrial fibrillation.</a><span class="one_line_source">[N Engl J Med.  2009]</span><div class="alt-note">
<div class="authors">Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators</div>
<div class="citation">N Engl J Med. 2009 Sep 17; 361(12):1139-51.</div>
</div>
</li>
<li class="two_line" reference_id="b30">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/21570107/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Vitamin K antagonists--current concepts and challenges.</a><span class="one_line_source">[Thromb Res.  2011]</span><div class="alt-note">
<div class="authors">Moualla H, Garcia D</div>
<div class="citation">Thromb Res. 2011 Sep; 128(3):210-5.</div>
</div>
</li>
<li class="two_line" reference_id="b18">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/20135071/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.</a><span class="one_line_source">[Thromb Haemost.  2010]</span><div class="alt-note">
<div class="authors">Ufer M</div>
<div class="citation">Thromb Haemost. 2010 Mar; 103(3):572-85.</div>
</div>
</li>
<li class="two_line" reference_id="b31">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/21674571/" ref="reftype=pubmed&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Practical aspects of the oral new anticoagulants.</a><span class="one_line_source">[Am J Hematol.  2011]</span><div class="alt-note">
<div class="authors">DeLoughery TG</div>
<div class="citation">Am J Hematol. 2011 Jul; 86(7):586-90.</div>
</div>
</li>
</ul></div>
</div>
</div>   
    </div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="./PMC3477350_files/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"><div id="body-link-popper-b1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.<div class="authors">Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, Rathgen K, Svärd R</div><div class="citation">J Clin Pharmacol. 2005 May; 45(5):555-63.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15831779/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b1">Ref list</a>]</p></div><div id="body-link-popper-b6" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.<div class="authors">Stangier J, Rathgen K, Stähle H, Mazur D</div><div class="citation">Clin Pharmacokinet. 2010 Apr; 49(4):259-68.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20214409/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b6">Ref list</a>]</p></div><div id="body-link-popper-b7" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">7. <span class="element-citation">Boehringer Ingelheim, Burlington, ON. <span class="ref-journal">Pradax™ Product Monograph [Internet]</span> 2012.  Available at  <a href="http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&amp;code=84384" ref="reftype=extlink&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&amp;code=84384</a> (last accessed 28 February 2012)</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b7">Ref list</a>]</div><div id="body-link-popper-b9" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">9. <span class="element-citation">Biotech Pharma News [Internet] Boehringer Ingelheim: PRAZAXA (dabigatran etexilate) approved in Japan for stroke prevention in atrial fibrillation. 2011.  Available at  <a href="http://www.biotechpharmanews.com/news/37-jan-2011/634-boehringer-ingelheim-prazaxa-dabigatran-etexilate-approved-in-japan-for-stroke-prevention-in-atrial-fibrillation.html" ref="reftype=extlink&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://www.biotechpharmanews.com/news/37-jan-2011/634-boehringer-ingelheim-prazaxa-dabigatran-etexilate-approved-in-japan-for-stroke-prevention-in-atrial-fibrillation.html</a> (last accessed 28 February 2012)</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b9">Ref list</a>]</div><div id="body-link-popper-b2" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.<div class="authors">Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W</div><div class="citation">Drug Metab Dispos. 2008 Feb; 36(2):386-99.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18006647/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b2">Ref list</a>]</p></div><div id="body-link-popper-b3" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.<div class="authors">Stangier J, Rathgen K, Stähle H, Gansser D, Roth W</div><div class="citation">Br J Clin Pharmacol. 2007 Sep; 64(3):292-303.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17506785/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b3">Ref list</a>]</p></div><div id="body-link-popper-b10" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.<div class="authors">Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR, RE-MODEL Study Group</div><div class="citation">J Thromb Haemost. 2007 Nov; 5(11):2178-85.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17764540/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b10">Ref list</a>]</p></div><div id="body-link-popper-b13" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Dabigatran versus warfarin in patients with atrial fibrillation.<div class="authors">Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators</div><div class="citation">N Engl J Med. 2009 Sep 17; 361(12):1139-51.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19717844/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b13">Ref list</a>]</p></div><div id="body-link-popper-b14" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">14. <span class="element-citation">Stangier J, Stähle H, Rathgen K, Reseski K, Kornicke T. Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug. <span><span class="ref-journal">J Thromb Haemost. </span>2007;<span class="ref-vol">5</span>(Suppl. 2)</span> Abstract P-W-677.</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b14">Ref list</a>]</div><div id="body-link-popper-b16" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.<div class="authors">Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W</div><div class="citation">Am J Cardiovasc Drugs. 2009; 9(1):59-68.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19178132/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b16">Ref list</a>]</p></div><div id="body-link-popper-b17" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">17. <span class="element-citation">Boehringer Ingelheim, Ridgefield, CT. Pradaxa® US prescribing information [Internet] 2012.  Available at  <a href="http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&amp;folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf" ref="reftype=extlink&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&amp;folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf</a> (last accessed 28 February 2012)</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b17">Ref list</a>]</div><div id="body-link-popper-b18" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.<div class="authors">Ufer M</div><div class="citation">Thromb Haemost. 2010 Mar; 103(3):572-85.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20135071/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b18">Ref list</a>]</p></div><div id="body-link-popper-b19" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Rifampin drastically reduces plasma concentrations and effects of oral midazolam.<div class="authors">Backman JT, Olkkola KT, Neuvonen PJ</div><div class="citation">Clin Pharmacol Ther. 1996 Jan; 59(1):7-13.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8549036/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b19">Ref list</a>]</p></div><div id="body-link-popper-b20" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.<div class="authors">Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ</div><div class="citation">Eur J Clin Pharmacol. 1998 Mar; 54(1):53-8.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9591931/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b20">Ref list</a>]</p></div><div id="body-link-popper-b21" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.<div class="authors">Galteau MM, Shamsa F</div><div class="citation">Eur J Clin Pharmacol. 2003 Dec; 59(10):713-33.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14605790/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b21">Ref list</a>]</p></div><div id="body-link-popper-b22" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">The analysis of multiple endpoints in clinical trials.<div class="authors">Pocock SJ, Geller NL, Tsiatis AA</div><div class="citation">Biometrics. 1987 Sep; 43(3):487-98.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/3663814/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b22">Ref list</a>]</p></div><div id="body-link-popper-b23" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">23. <span class="element-citation">Advisory Committee Briefing Document [Internet] Dabigatran etexilate. 2010.  Boehringer Ingelheim; Available at  <a href="http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf" ref="reftype=extlink&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf</a> (last accessed 4 April 2011)</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b23">Ref list</a>]</div><div id="body-link-popper-b8" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">8. <span class="element-citation">FDA [Internet] Pradaxa label. 2010.  Available at  <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022512s000lbl.pdf" ref="reftype=extlink&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022512s000lbl.pdf</a> (last accessed 6 April 2011)</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b8">Ref list</a>]</div><div id="body-link-popper-b24" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction.<div class="authors">Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, Martin DE</div><div class="citation">J Clin Pharmacol. 1999 May; 39(5):487-94.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10234596/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b24">Ref list</a>]</p></div><div id="body-link-popper-b25" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Pharmacokinetic interactions with rifampicin : clinical relevance.<div class="authors">Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT</div><div class="citation">Clin Pharmacokinet. 2003; 42(9):819-50.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12882588/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b25">Ref list</a>]</p></div><div id="body-link-popper-b26" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors.<div class="authors">Gupta A, Mugundu GM, Desai PB, Thummel KE, Unadkat JD</div><div class="citation">Drug Metab Dispos. 2008 Jun; 36(6):1172-80.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18332086/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b26">Ref list</a>]</p></div><div id="body-link-popper-b27" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.<div class="authors">Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK</div><div class="citation">J Clin Invest. 1999 Jul; 104(2):147-53.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10411543/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b27">Ref list</a>]</p></div><div id="body-link-popper-b28" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.<div class="authors">Tapaninen T, Neuvonen PJ, Niemi M</div><div class="citation">Eur J Clin Pharmacol. 2010 May; 66(5):497-502.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20179914/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b28">Ref list</a>]</p></div><div id="body-link-popper-b29" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">29. <span class="element-citation">Kishimoto W, Ishiguro N, Saito A, Ebner T, Haertter S, Igarashi T. Characterization of drug transporters involved in the disposition of dabigatran etexilate and its active form, dabigatran. 9th Int Mtg Int Soc Study Xenobiotics (ISSX), Istanbul, 4–8 Sep 2010. <span><span class="ref-journal">Drug Metab Rev. </span>2010;<span class="ref-vol">42</span>:293.</span> Abstr P469.</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b29">Ref list</a>]</div><div id="body-link-popper-b30" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Vitamin K antagonists--current concepts and challenges.<div class="authors">Moualla H, Garcia D</div><div class="citation">Thromb Res. 2011 Sep; 128(3):210-5.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/21570107/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b30">Ref list</a>]</p></div><div id="body-link-popper-b31" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Practical aspects of the oral new anticoagulants.<div class="authors">DeLoughery TG</div><div class="citation">Am J Hematol. 2011 Jul; 86(7):586-90.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/21674571/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b31">Ref list</a>]</p></div><div id="body-link-popper-b32" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">32. <span class="element-citation">Boehringer Ingelheim, Ingelheim. Pradaxa® summary of product characteristics [Internet] 2011.  Available at  <a href="http://www.medicines.org.uk/emc/medicine/20760/SPC/Pradaxa+110+mg+hard+capsules" ref="reftype=extlink&amp;article-id=3477350&amp;issue-id=215557&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://www.medicines.org.uk/emc/medicine/20760/SPC/Pradaxa+110+mg+hard+capsules</a> (last accessed 28 February 2012)</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#b32">Ref list</a>]</div></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <div class="breadcrumbs">You are here: 
            <span id="breadcrumb_text"><a href="http://www.ncbi.nlm.nih.gov/guide/">NCBI</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central (PMC)</a></span></div>
    <a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target="_blank" href="http://www.ncbi.nlm.nih.gov/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-23T14:29:55-04:00&amp;Host=ptpmc202">Write to the Help Desk</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="./PMC3477350_files/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="http://www.nlm.nih.gov/" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="http://www.nih.gov/" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="http://www.dhhs.gov/" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="http://www.usa.gov/" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            
            <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Copyright</a> | <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html#disclaimer">Disclaimer</a> |
            <a href="http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a> | 
            <a href="http://www.ncbi.nlm.nih.gov/guide/browsers/">Browsers</a> | <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a> | <a href="http://www.ncbi.nlm.nih.gov/About/glance/contact_info.html">Contact</a>
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="http://www.ncbi.nlm.nih.gov/">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url"><a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
        </div>
    </div>
    <script type="text/javascript" src="./PMC3477350_files/InstrumentPageStarterJS.js"> </script>    
    <script type="text/javascript" src="./PMC3477350_files/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div><div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 63.5938px; left: 408.188px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: none;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477350/#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: none;">Turn off</a></div></div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript>&lt;img alt="statistics" src="/stat?jsdisabled=true&amp;amp;ncbi_db=pmc&amp;amp;ncbi_pdid=article&amp;amp;ncbi_acc=&amp;amp;ncbi_domain=brjclinpharm&amp;amp;ncbi_report=record&amp;amp;ncbi_type=fulltext&amp;amp;ncbi_objectid=&amp;amp;ncbi_pcid=/articles/PMC3477350/&amp;amp;ncbi_app=pmc" /&gt;</noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- F4FC7E8376854741_0014SID /projects/PMC/PMCViewer@4.35 ptpmc202 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->

<script type="text/javascript" src="./PMC3477350_files/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1" style="display: none;"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div><ul class="print-log"><li></li></ul></body></html>